pioglitazone has been researched along with Cardiac Failure in 83 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function." | 9.41 | In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. ( Bell, DSH; Jerkins, T, 2023) |
| "To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial." | 9.30 | Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019) |
| "The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients." | 9.27 | Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, A; Pfau, SE; Schwartz, GG; Spatz, ES; Viscoli, CM; Young, LH, 2018) |
| "Efficacy [myocardial infarction (MI) or recurrent stroke] new-onset diabetes) and adverse outcomes (oedema, weight gain, heart failure and bone fracture) were examined for subjects assigned to pioglitazone or placebo within strata defined by mode dose of study drug taken (i." | 9.22 | Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. ( Abdul-Ghani, M; Dandona, P; DeFronzo, R; Furie, K; Inzucchi, SE; Kernan, WN; Spence, JD; Viscoli, C; Young, LH, 2022) |
| "Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications." | 9.14 | Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009) |
| "Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure." | 9.12 | Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). ( Charbonnel, B; Dormandy, JA; Erdmann, E; Massi-Benedetti, M; Skene, AM; Spanheimer, R; Standl, E; Tan, M; Wilcox, RG; Yates, J, 2007) |
| "To evaluate the effect of SGLT2is, pioglitazone, and their combination on the risk of major adverse cardiovascular events (MACE) and heart failure in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease." | 8.31 | Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. ( Huang, CN; Huang, JY; Kornelius, E; Liao, PL; Lo, SC; Yang, YS, 2023) |
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 8.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| "Individual end points of acute myocardial infarction (AMI), stroke, heart failure, and all-cause mortality (death), and composite end point of AMI, stroke, heart failure, or death, assessed using incidence rates by thiazolidinedione, attributable risk, number needed to harm, Kaplan-Meier plots of time to event, and Cox proportional hazard ratios for time to event, adjusted for potential confounding factors, with pioglitazone as reference." | 7.76 | Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. ( Ali, F; Graham, DJ; Kelman, JA; MaCurdy, TE; Ouellet-Hellstrom, R; Sholley, C; Worrall, C, 2010) |
| "Pioglitazone can attenuate congestive heart failure-induced atrial structural remodeling and AF promotion, with effects similar to those of candesartan." | 7.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "Pioglitazone improved LV remodeling and function in mice with post-MI heart failure." | 7.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| "Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function." | 5.41 | In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. ( Bell, DSH; Jerkins, T, 2023) |
| "This study of patients with Type 2 diabetes failed to find evidence that short-term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first-line diabetes therapy." | 5.33 | Pioglitazone initiation and subsequent hospitalization for congestive heart failure. ( Ahmed, AT; Karter, AJ; Liu, J; Moffet, HH; Parker, MM, 2005) |
| "Patients with type 2 diabetes aged > or =18 years who had begun treatment with pioglitazone or insulin between January 1999 and December 2001 were identified using the PharMetrics Patient-Centric database." | 5.32 | Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. ( Fernandes, AW; Khan, M; Murray, FT; Rajagopalan, R; Rosenson, RS, 2004) |
| "To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial." | 5.30 | Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019) |
| "The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients." | 5.27 | Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, A; Pfau, SE; Schwartz, GG; Spatz, ES; Viscoli, CM; Young, LH, 2018) |
| "Efficacy [myocardial infarction (MI) or recurrent stroke] new-onset diabetes) and adverse outcomes (oedema, weight gain, heart failure and bone fracture) were examined for subjects assigned to pioglitazone or placebo within strata defined by mode dose of study drug taken (i." | 5.22 | Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. ( Abdul-Ghani, M; Dandona, P; DeFronzo, R; Furie, K; Inzucchi, SE; Kernan, WN; Spence, JD; Viscoli, C; Young, LH, 2022) |
| " The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline." | 5.14 | Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010) |
| "Treatment of pioglitazone reduced neointimal hyperplasia in patients with STEMI treated with primary stent implantation without placing the patient at increased risk of complications." | 5.14 | Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. ( Domae, H; Kaneda, H; Matsumi, J; Minami, Y; Miyashita, Y; Mizuno, S; Saito, S; Shiono, T; Sugitatsu, K; Takahashi, S; Taketani, Y, 2009) |
| "Pioglitazone (PIO), a thiazolidinedione (TZD), is reported to be highly effective in the treatment of type 2 diabetes mellitus, but is associated with edema, heart failure, and weight gain." | 5.14 | Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. ( Bailey, AL; Chan, JY; Grossman, LD; Parlan, G; Yee, G; Yu, M, 2009) |
| "Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure." | 5.12 | Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). ( Charbonnel, B; Dormandy, JA; Erdmann, E; Massi-Benedetti, M; Skene, AM; Spanheimer, R; Standl, E; Tan, M; Wilcox, RG; Yates, J, 2007) |
| " The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women." | 4.89 | [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus]. ( de Pablos-Velasco, PL; Valerón, PF, 2013) |
| "To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglitazone) on myocardial infarction, congestive heart failure, and mortality in patients with type 2 diabetes." | 4.87 | Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. ( Kwok, CS; Loke, YK; Singh, S, 2011) |
| " 3041 were excluded, and we did a systematic review and meta-analysis of the seven remaining randomised double-blind clinical trials of drug-related congestive heart failure in patients given TZDs (either rosiglitazone or pioglitazone)." | 4.84 | Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. ( Lago, RM; Nesto, RW; Singh, PP, 2007) |
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 4.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| "To evaluate the effect of SGLT2is, pioglitazone, and their combination on the risk of major adverse cardiovascular events (MACE) and heart failure in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease." | 4.31 | Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. ( Huang, CN; Huang, JY; Kornelius, E; Liao, PL; Lo, SC; Yang, YS, 2023) |
| " Pioglitazone use was determined in 6-month study intervals, with outcome events of myocardial infarction (MI), ischemic stroke, and heart failure." | 3.91 | Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes. ( Dong, X; Du, X; Jing, S; Liu, Y; Miao, S; Wang, L; Xu, H; Xu, T; Zhang, X, 2019) |
| "Sequence symmetry analyses were undertaken to investigate the risk of peripheral oedema, as measured by incident furosemide dispensing, and risk of hospitalisations for heart failure." | 3.81 | Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. ( Chan, EW; Choi, NK; Griffiths, J; Kimura, M; Kimura, T; Kubota, K; Lai, EC; Man, KK; Nguyen, TA; Ooba, N; Park, BJ; Pratt, NL; Roughead, EE; Sato, T; Shin, JY; Wang, T; Wong, IC; Yang, YH, 2015) |
| " Treatment with pioglitazone improved heart function by decreasing the expression of AGEs and OX-62 in the rats with myocardial infarction (MI) plus diabetes." | 3.80 | Advanced glycation end products promote heart failure through inducing the immune maturation of dendritic cells. ( Cao, W; Chen, J; Chen, X; Chen, Y; Liu, P, 2014) |
| " The risk of all-cause mortality was also significantly lower in the PIO cohort than the INS cohort among subgroups based on baseline variables such as sex, age (<55 years, ≥55 years), antidiabetic medication use (sulfonylureas or metformin), lipid-altering medication use, and congestive heart failure status." | 3.80 | A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. ( Bron, M; Joseph, G; Liang, H; Perez, A; Vallarino, C; Yang, J; Yu, S, 2014) |
| "This population-based cohort study shows that rosiglitazone imposes a higher risk of developing stroke or heart failure in this Asian patient population, suggesting the adverse side effects of rosiglitazone across ethnic boundaries." | 3.79 | Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. ( Chen, PC; Chen, RC; Hsu, CY; Lu, CJ; Muo, CH; Sun, Y, 2013) |
| "The aim of this study was to conduct a direct comparison of TZDs (pioglitazone and rosiglitazone) and their relationship to cardiovascular events (myocardial infarction [MI], angina, congestive heart failure [CHF], and cerebral vascular accident [CVA]) in Taiwanese patients with type 2 diabetes mellitus (DM)." | 3.77 | Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. ( Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC, 2011) |
| "Higher risks for death (overall and due to cardiovascular disease) and heart failure were found for rosiglitazone compared to pioglitazone." | 3.77 | Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. ( Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP, 2011) |
| "This study directly compares risk of acute myocardial infarction (AMI), acute heart failure (AHF), or all-cause death among pioglitazone- and rosiglitazone-treated patients in a managed-care population." | 3.76 | Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. ( Bohn, RL; Chang, CL; Cziraky, MJ; Sarawate, CA; Wertz, DA; Willey, VJ, 2010) |
| "Individual end points of acute myocardial infarction (AMI), stroke, heart failure, and all-cause mortality (death), and composite end point of AMI, stroke, heart failure, or death, assessed using incidence rates by thiazolidinedione, attributable risk, number needed to harm, Kaplan-Meier plots of time to event, and Cox proportional hazard ratios for time to event, adjusted for potential confounding factors, with pioglitazone as reference." | 3.76 | Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. ( Ali, F; Graham, DJ; Kelman, JA; MaCurdy, TE; Ouellet-Hellstrom, R; Sholley, C; Worrall, C, 2010) |
| "To compare the risk of acute myocardial infarction, heart failure, and death in patients with type 2 diabetes treated with rosiglitazone and pioglitazone." | 3.75 | Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. ( Austin, PC; Gomes, T; Hux, JE; Juurlink, DN; Lipscombe, LL; Mamdani, MM, 2009) |
| "In this population-based study of older patients with diabetes, TZD treatment, primarily with rosiglitazone, was associated with an increased risk of congestive heart failure, acute myocardial infarction, and mortality when compared with other combination oral hypoglycemic agent treatments." | 3.74 | Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. ( Alter, DA; Gomes, T; Hux, JE; Juurlink, DN; Lévesque, LE; Lipscombe, LL, 2007) |
| "Pioglitazone can attenuate congestive heart failure-induced atrial structural remodeling and AF promotion, with effects similar to those of candesartan." | 3.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "Our findings from a large population-based cohort of US seniors are compatible with an increased risk of all-cause mortality and congestive heart failure in patients initiating therapy with rosiglitazone compared with similar patients initiating therapy with pioglitazone." | 3.74 | Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. ( Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC, 2008) |
| "Pioglitazone improved LV remodeling and function in mice with post-MI heart failure." | 3.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| "There is a bi-directional link between type 2 diabetes mellitus (T2DM) and heart failure (HF) and their co-existence markedly increases an individual's morbidity and mortality." | 2.82 | Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. ( Katsiki, N; Kazakos, K; Triposkiadis, F, 2022) |
| "Heart failure (HF) and nonalcoholic fatty liver disease (NAFLD) are 2 conditions that have become important global public health problems." | 2.82 | Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. ( Benfari, G; Bonapace, S; Byrne, CD; Mantovani, A; Simon, TG; Targher, G, 2022) |
| "Pioglitazone is a thiazolidinedione that displays high affinity for PPARγ(1) and PPARγ(2), which are predominately expressed in adipose tissue." | 2.46 | Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. ( Derosa, G, 2010) |
| "Pioglitazone was associated with reduced all-cause mortality [OR 0." | 2.44 | Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. ( Gensini, GF; Lamanna, C; Mannucci, E; Marchionni, N; Monami, M, 2008) |
| "The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments." | 2.42 | Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| "Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013." | 1.43 | Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. ( Balakrishnan, S; Brown, NJ; Fireman, BH; Graham, DJ; Griffin, MR; Hamilton, J; Hampp, C; Iyer, A; Lendle, S; Nathwani, N; Pimentel, M; Pucino, F; Reichman, ME; Rucker, M; Toh, S, 2016) |
| "The frequency of edema and cardiac failure was significantly higher with TZDs than in other patients (18% and 7." | 1.37 | Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. ( Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P, 2011) |
| "Incident myocardial infarction, congestive heart failure, and all cause mortality." | 1.35 | Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. ( Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR, 2009) |
| "Type 2 diabetes is a common disorder with an increased risk of macrovascular complications." | 1.35 | Type 2 diabetes, thiazolidinediones, and cardiovascular risk. ( Hobbs, FD; Taylor, C, 2009) |
| "This study of patients with Type 2 diabetes failed to find evidence that short-term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first-line diabetes therapy." | 1.33 | Pioglitazone initiation and subsequent hospitalization for congestive heart failure. ( Ahmed, AT; Karter, AJ; Liu, J; Moffet, HH; Parker, MM, 2005) |
| "To determine, in patients with type 2 diabetes mellitus, whether an association exists between thiazolidinedione therapy or other diabetes therapies and hospital admission for heart failure." | 1.33 | Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. ( Bultemeier, NC; Hartung, DM; Haxby, DG; Touchette, DR, 2005) |
| "The use of PPAR-gamma agonists in the treatment of heart failure is, however, controversial." | 1.32 | Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure. ( Thiemermann, C, 2004) |
| "Patients with type 2 diabetes aged > or =18 years who had begun treatment with pioglitazone or insulin between January 1999 and December 2001 were identified using the PharMetrics Patient-Centric database." | 1.32 | Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. ( Fernandes, AW; Khan, M; Murray, FT; Rajagopalan, R; Rosenson, RS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 43 (51.81) | 29.6817 |
| 2010's | 33 (39.76) | 24.3611 |
| 2020's | 7 (8.43) | 2.80 |
| Authors | Studies |
|---|---|
| Mantovani, A | 1 |
| Byrne, CD | 1 |
| Benfari, G | 1 |
| Bonapace, S | 1 |
| Simon, TG | 1 |
| Targher, G | 2 |
| Spence, JD | 2 |
| Viscoli, C | 1 |
| Kernan, WN | 3 |
| Young, LH | 3 |
| Furie, K | 1 |
| DeFronzo, R | 1 |
| Abdul-Ghani, M | 1 |
| Dandona, P | 1 |
| Inzucchi, SE | 3 |
| Mannucci, E | 2 |
| Gallo, M | 1 |
| Giaccari, A | 1 |
| Candido, R | 1 |
| Pintaudi, B | 1 |
| Monami, M | 2 |
| Katsiki, N | 1 |
| Kazakos, K | 1 |
| Triposkiadis, F | 1 |
| Lo, SC | 1 |
| Kornelius, E | 1 |
| Liao, PL | 1 |
| Huang, JY | 1 |
| Yang, YS | 1 |
| Huang, CN | 1 |
| Yoo, J | 1 |
| Jeon, J | 1 |
| Baik, M | 1 |
| Kim, J | 1 |
| Bell, DSH | 1 |
| Jerkins, T | 1 |
| Legchenko, E | 1 |
| Chouvarine, P | 1 |
| Borchert, P | 1 |
| Fernandez-Gonzalez, A | 1 |
| Snay, E | 1 |
| Meier, M | 1 |
| Maegel, L | 1 |
| Mitsialis, SA | 1 |
| Rog-Zielinska, EA | 1 |
| Kourembanas, S | 1 |
| Jonigk, D | 1 |
| Hansmann, G | 1 |
| Lim, GB | 1 |
| Viscoli, CM | 2 |
| Schwartz, GG | 1 |
| Curtis, JP | 1 |
| Gorman, MJ | 1 |
| Furie, KL | 2 |
| Conwit, R | 1 |
| Spatz, ES | 1 |
| Lovejoy, A | 1 |
| Abbott, JD | 1 |
| Jacoby, DL | 1 |
| Kolansky, DM | 1 |
| Ling, FS | 1 |
| Pfau, SE | 1 |
| Tomlin, AM | 1 |
| Woods, DJ | 1 |
| Lloyd, HS | 1 |
| Stewart, RAH | 1 |
| Tilyard, MW | 1 |
| Dawson, J | 1 |
| Miao, S | 1 |
| Dong, X | 1 |
| Zhang, X | 2 |
| Jing, S | 1 |
| Xu, T | 1 |
| Wang, L | 1 |
| Du, X | 1 |
| Xu, H | 1 |
| Liu, Y | 1 |
| Dearborn-Tomazos, J | 1 |
| Ford, GA | 1 |
| Gorman, M | 1 |
| Lovejoy, AM | 1 |
| Lu, CJ | 1 |
| Sun, Y | 1 |
| Muo, CH | 1 |
| Chen, RC | 1 |
| Chen, PC | 1 |
| Hsu, CY | 1 |
| Valerón, PF | 1 |
| de Pablos-Velasco, PL | 1 |
| Cao, W | 1 |
| Chen, J | 1 |
| Chen, Y | 1 |
| Chen, X | 1 |
| Liu, P | 1 |
| Yang, J | 1 |
| Vallarino, C | 1 |
| Bron, M | 1 |
| Perez, A | 1 |
| Liang, H | 1 |
| Joseph, G | 1 |
| Yu, S | 1 |
| Breunig, IM | 1 |
| Shaya, FT | 1 |
| McPherson, ML | 1 |
| Snitker, S | 1 |
| Dangi-Garimella, S | 1 |
| Seong, JM | 1 |
| Choi, NK | 2 |
| Shin, JY | 2 |
| Chang, Y | 1 |
| Kim, YJ | 1 |
| Lee, J | 1 |
| Kim, JY | 1 |
| Park, BJ | 2 |
| Roughead, EE | 1 |
| Chan, EW | 1 |
| Kimura, M | 1 |
| Kimura, T | 1 |
| Kubota, K | 1 |
| Lai, EC | 1 |
| Man, KK | 1 |
| Nguyen, TA | 1 |
| Ooba, N | 1 |
| Sato, T | 1 |
| Wang, T | 1 |
| Griffiths, J | 1 |
| Wong, IC | 1 |
| Yang, YH | 1 |
| Pratt, NL | 1 |
| Kamimura, D | 1 |
| Uchino, K | 1 |
| Ishigami, T | 1 |
| Hall, ME | 1 |
| Umemura, S | 1 |
| Toh, S | 1 |
| Hampp, C | 1 |
| Reichman, ME | 1 |
| Graham, DJ | 2 |
| Balakrishnan, S | 1 |
| Pucino, F | 1 |
| Hamilton, J | 1 |
| Lendle, S | 1 |
| Iyer, A | 1 |
| Rucker, M | 1 |
| Pimentel, M | 1 |
| Nathwani, N | 1 |
| Griffin, MR | 1 |
| Brown, NJ | 1 |
| Fireman, BH | 1 |
| Adachi, H | 1 |
| Katsuyama, H | 1 |
| Yanai, H | 1 |
| Kenny, C | 1 |
| Stafylas, PC | 1 |
| Sarafidis, PA | 1 |
| Lasaridis, AN | 1 |
| Singh, S | 2 |
| Furberg, CD | 1 |
| Winkelmayer, WC | 1 |
| Setoguchi, S | 1 |
| Levin, R | 1 |
| Solomon, DH | 1 |
| Finsterer, J | 1 |
| Stöllberger, C | 1 |
| Grossman, LD | 1 |
| Parlan, G | 1 |
| Bailey, AL | 1 |
| Yee, G | 1 |
| Yu, M | 1 |
| Chan, JY | 1 |
| Kaneda, H | 1 |
| Shiono, T | 1 |
| Miyashita, Y | 1 |
| Takahashi, S | 1 |
| Taketani, Y | 1 |
| Domae, H | 1 |
| Matsumi, J | 1 |
| Mizuno, S | 1 |
| Minami, Y | 1 |
| Sugitatsu, K | 1 |
| Saito, S | 1 |
| Viljoen, A | 1 |
| Sinclair, A | 1 |
| Taylor, C | 1 |
| Hobbs, FD | 1 |
| Juurlink, DN | 3 |
| Gomes, T | 2 |
| Lipscombe, LL | 2 |
| Austin, PC | 1 |
| Hux, JE | 2 |
| Mamdani, MM | 1 |
| de Vries, CS | 1 |
| Russell-Jones, DL | 1 |
| Lambley, RG | 1 |
| Vahdani, K | 2 |
| Konstantinidis, A | 1 |
| Booth, A | 1 |
| Tzoulaki, I | 1 |
| Molokhia, M | 1 |
| Curcin, V | 1 |
| Little, MP | 1 |
| Millett, CJ | 1 |
| Ng, A | 1 |
| Hughes, RI | 1 |
| Khunti, K | 1 |
| Wilkins, MR | 1 |
| Majeed, A | 1 |
| Elliott, P | 1 |
| Pala, S | 1 |
| Esen, O | 1 |
| Akçakoyun, M | 1 |
| Kahveci, G | 1 |
| Kargin, R | 1 |
| Tigen, K | 1 |
| Karaahmet, T | 1 |
| Açar, G | 1 |
| Esen, AM | 1 |
| Kirma, C | 1 |
| Kaul, S | 1 |
| Bolger, AF | 1 |
| Herrington, D | 1 |
| Giugliano, RP | 1 |
| Eckel, RH | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Ouellet-Hellstrom, R | 1 |
| MaCurdy, TE | 1 |
| Ali, F | 1 |
| Sholley, C | 1 |
| Worrall, C | 1 |
| Kelman, JA | 1 |
| Wertz, DA | 1 |
| Chang, CL | 1 |
| Sarawate, CA | 1 |
| Willey, VJ | 1 |
| Cziraky, MJ | 1 |
| Bohn, RL | 1 |
| Derosa, G | 1 |
| Erdmann, E | 3 |
| Spanheimer, R | 2 |
| Charbonnel, B | 2 |
| Lipska, KJ | 1 |
| Ross, JS | 1 |
| Loke, YK | 1 |
| Kwok, CS | 1 |
| Berthet, S | 1 |
| Olivier, P | 1 |
| Montastruc, JL | 1 |
| Lapeyre-Mestre, M | 1 |
| Pfister, R | 1 |
| Cairns, R | 1 |
| Schneider, CA | 1 |
| Yu, Y | 1 |
| Zhang, ZH | 1 |
| Wei, SG | 1 |
| Weiss, RM | 1 |
| Felder, RB | 1 |
| Wang, CC | 1 |
| Chen, WL | 1 |
| Kao, TW | 1 |
| Chang, YW | 1 |
| Loh, CH | 1 |
| Chou, CC | 2 |
| Gallagher, AM | 1 |
| Smeeth, L | 1 |
| Seabroke, S | 1 |
| Leufkens, HG | 1 |
| van Staa, TP | 1 |
| Shiomi, T | 1 |
| Tsutsui, H | 1 |
| Hayashidani, S | 1 |
| Suematsu, N | 1 |
| Ikeuchi, M | 1 |
| Wen, J | 1 |
| Ishibashi, M | 1 |
| Kubota, T | 1 |
| Egashira, K | 1 |
| Takeshita, A | 1 |
| Apolito, RA | 1 |
| Ogawa, S | 1 |
| Takeuchi, K | 1 |
| Ito, S | 1 |
| Buse, JB | 1 |
| Papoushek, C | 1 |
| Thiemermann, C | 1 |
| Jamieson, A | 1 |
| Abousleiman, Y | 1 |
| Belcher, G | 1 |
| Lambert, C | 1 |
| Goh, KL | 1 |
| Edwards, G | 1 |
| Valbuena, M | 1 |
| Rajagopalan, R | 1 |
| Rosenson, RS | 1 |
| Fernandes, AW | 1 |
| Khan, M | 1 |
| Murray, FT | 1 |
| Shah, M | 1 |
| Kolandaivelu, A | 1 |
| Fearon, WF | 1 |
| Karter, AJ | 1 |
| Ahmed, AT | 1 |
| Liu, J | 1 |
| Moffet, HH | 1 |
| Parker, MM | 1 |
| Hartung, DM | 1 |
| Touchette, DR | 1 |
| Bultemeier, NC | 1 |
| Haxby, DG | 1 |
| Holman, RR | 1 |
| Retnakaran, R | 1 |
| Farmer, A | 1 |
| Stevens, R | 1 |
| Irons, BK | 1 |
| Greene, RS | 1 |
| Mazzolini, TA | 1 |
| Edwards, KL | 1 |
| Sleeper, RB | 1 |
| Rydén, L | 1 |
| Thráinsdóttir, I | 1 |
| Swedberg, K | 1 |
| Iqbal, MB | 1 |
| Fisher, NG | 1 |
| Lyne, JC | 1 |
| McDonagh, TA | 1 |
| Westerbacka, J | 1 |
| Wilcox, RG | 1 |
| Skene, AM | 1 |
| Massi-Benedetti, M | 1 |
| Yates, J | 1 |
| Tan, M | 1 |
| Standl, E | 1 |
| Dormandy, JA | 1 |
| Lago, RM | 1 |
| Singh, PP | 1 |
| Nesto, RW | 1 |
| Lévesque, LE | 1 |
| Alter, DA | 1 |
| D'Arrigo, T | 1 |
| Shimano, M | 1 |
| Tsuji, Y | 1 |
| Inden, Y | 1 |
| Kitamura, K | 1 |
| Uchikawa, T | 1 |
| Harata, S | 1 |
| Nattel, S | 1 |
| Murohara, T | 1 |
| Wilson, LD | 1 |
| Tsai, CT | 1 |
| Korantzopoulos, P | 1 |
| Goudevenos, JA | 1 |
| Liu, T | 1 |
| Li, G | 1 |
| Lamanna, C | 1 |
| Gensini, GF | 1 |
| Marchionni, N | 1 |
| Benbow, A | 1 |
| Stewart, M | 1 |
| Yeoman, G | 1 |
| Kobayashi, M | 1 |
| Iwata, M | 1 |
| Wooltorton, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949] | Phase 3 | 3,876 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis[NCT01210989] | 60 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Study of PPAR-Gamma Agonist-Rosiglitazone for Determining Cardiac Adverse Effects in Type 2 Diabetic Patients[NCT00300911] | Phase 4 | 45 participants | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 136 |
| Placebo | 146 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | 0.29 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 73 |
| Placebo | 149 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 127 |
| Placebo | 154 |
(NCT00091949)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 175 |
| Placebo | 228 |
17 reviews available for pioglitazone and Cardiac Failure
| Article | Year |
|---|---|
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week.
Topics: Bariatric Surgery; Dysbiosis; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hypoglycemic | 2022 |
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin Re | 2022 |
Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.
Topics: Adult; Albuminuria; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Glucagon-Like Pe | 2023 |
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
Topics: Contraindications, Drug; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Lik | 2022 |
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome.
Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Insul | 2023 |
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Comb | 2013 |
Rosiglitazone and the thiazolidinediones: a changing context.
Topics: Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazo | 2007 |
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Edema; Heart Failure; Humans; Pioglitazone; | 2009 |
Safety and efficacy of rosiglitazone in the elderly diabetic patient.
Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fra | 2009 |
Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
Topics: Administration, Oral; Blood Glucose; Cardiovascular System; Diabetes Mellitus, Type 2; Edema; Fractu | 2010 |
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Piogli | 2011 |
The "glitazones": rosiglitazone and pioglitazone.
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Female; Heart Failure; Humans; Hypo | 2003 |
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl | 2004 |
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heart Failure; Humans; H | 2006 |
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; H | 2007 |
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
Topics: Aged; Cause of Death; Coronary Disease; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycem | 2008 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
9 trials available for pioglitazone and Cardiac Failure
| Article | Year |
|---|---|
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
Topics: Aged; Aged, 80 and over; Australia; Double-Blind Method; Europe; Female; Heart Failure; Hospitalizat | 2018 |
Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycated Hemo | 2019 |
Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Edema; Female; Fol | 2009 |
Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; | 2009 |
Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study.
Topics: Blood Pressure; Cardiovascular System; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Female; | 2010 |
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Topics: Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic An | 2010 |
A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studi | 2013 |
Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.
Topics: Aged; Atrial Natriuretic Factor; Body Mass Index; Buformin; Diabetes Mellitus, Type 2; Female; Glyca | 2003 |
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Hear | 2007 |
57 other studies available for pioglitazone and Cardiac Failure
| Article | Year |
|---|---|
Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Piog | 2023 |
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin | 2023 |
PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.
Topics: Fatty Acids; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Oxidation-R | 2018 |
Treatment of PAH with a PPARγ agonist.
Topics: Heart Failure; Humans; Hypertension, Pulmonary; Pioglitazone; PPAR gamma | 2018 |
Understanding medicines with a propensity to increase the risk of heart failure: Combining existing knowledge with targeted population assessment.
Topics: Aged; Aged, 80 and over; Albuterol; Antifungal Agents; Case-Control Studies; Clozapine; Diltiazem; D | 2018 |
Pioglitazone Use After Stroke: Story of Hearts, Minds, and Bones.
Topics: Brain Ischemia; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Ischemic Attack, Transient; Pio | 2018 |
Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes.
Topics: Case-Control Studies; China; Diabetes Mellitus, Type 2; Electronic Health Records; Female; Follow-Up | 2019 |
Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart | 2013 |
Advanced glycation end products promote heart failure through inducing the immune maturation of dendritic cells.
Topics: Animals; Coculture Techniques; Dendritic Cells; Diabetes Complications; Dose-Response Relationship, | 2014 |
A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Insulin; | 2014 |
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Fema | 2014 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides | 2014 |
Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Topics: Adult; Aged; Cardiovascular Diseases; Cardiovascular System; Cohort Studies; Diabetes Mellitus, Type | 2015 |
Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries.
Topics: Databases, Factual; Edema; Ethnicity; Furosemide; Heart Failure; Hospitalization; Humans; Pioglitazo | 2015 |
Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism.
Topics: Animals; beta Catenin; Collagen Type I; Disease Models, Animal; Disease Progression; Fibrosis; Heart | 2016 |
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart | 2016 |
The low dose (7.5mg/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Ag | 2017 |
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Piogli | 2009 |
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; | 2008 |
Pioglitazone-induced heart failure in a patient with restrictive cardiomyopathy and metabolic myopathy.
Topics: Cardiomyopathy, Restrictive; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; | 2009 |
Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Piogl | 2009 |
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; | 2009 |
Rosiglitazone or pioglitazone in type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Piogli | 2009 |
Rosiglitazone and pioglitazone. Beware macular oedema.
Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular E | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
Topics: American Heart Association; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Fa | 2010 |
A consistency-adjusted alpha-adaptive strategy for sequential testing.
Topics: Algorithms; Biostatistics; Captopril; Clinical Trials as Topic; Data Interpretation, Statistical; Di | 2010 |
Rosiglitazone and the case for safety over certainty.
Topics: Decision Making; Diabetes Mellitus, Type 2; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Top | 2010 |
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; H | 2010 |
Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population.
Topics: Female; Heart Failure; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Piog | 2010 |
Switching from rosiglitazone: thinking outside the class.
Topics: Blood Glucose; Cardiovascular Diseases; Decision Making; Diabetes Mellitus; Drug Labeling; Evidence- | 2011 |
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; | 2011 |
Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.
Topics: Animals; Body Weight; Cytokines; Eating; Heart Failure; Inflammation; Male; Models, Animal; NF-kappa | 2012 |
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; C | 2011 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases | 2011 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Topics: Administration, Oral; Animals; Aspartate Aminotransferases; Blood Glucose; Cytokines; Disease Models | 2002 |
Initial management of glycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; In | 2003 |
Glitazones and heart failure: critical appraisal for the clinician.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diuretics; Edema; Heart Failure; | 2003 |
Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Topics: Animals; Disease Models, Animal; Heart Failure; Humans; Ligands; Mice; Myocardial Infarction; Piogli | 2004 |
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; | 2004 |
Thiazolidinedione-associated congestive heart failure and pulmonary edema.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; | 2004 |
Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Hospita | 2004 |
Pioglitazone-induced heart failure despite normal left ventricular function.
Topics: Aged; Diabetes Mellitus; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; | 2004 |
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Hospi | 2005 |
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Topics: Adult; Aged; Case-Control Studies; Chromans; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospi | 2005 |
PROactive study.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Models, Cardiovascular; Piogl | 2006 |
Adjudication of serious heart failure in patients from PROactive.
Topics: Heart Failure; Hospital Mortality; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Pneum | 2007 |
Thiazolinediones and heart failure: the potential to precipitate irreversible cardiac dysfunction.
Topics: Female; Heart Failure; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
PROactive in patients with type 2 diabetes and previous myocardial infarction: swinging the sword of Damocles?
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Piogli | 2007 |
Thiazolidinediones and cardiovascular disease.
Topics: Animals; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Rosiglitaz | 2007 |
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
Topics: Aged; Aged, 80 and over; Cause of Death; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglyce | 2007 |
Glitazones and your heart, revisited.
Topics: Heart Diseases; Heart Failure; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimi | 2008 |
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Comp | 2008 |
Role of pioglitazone treatment on atrial remodeling and atrial fibrillation (AF)promotion in an experimental model of congestive heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Heart | 2008 |
Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.
Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinedion | 2001 |
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.
Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinedion | 2002 |